Elliot Chartash

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

Michael E. Weinblatt, Edward Keystone, Daniel E. Furst et al. · Arthritis & Rheumatism · 2003 · 1.8K citations

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Paul Nghiem, Shailender Bhatia, Evan J. Lipson et al. · New England Journal of Medicine · 2016 · 1.2K citations · Full text

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

Edward Keystone, Arthur F. Kavanaugh, John T. Sharp et al. · Arthritis & Rheumatism · 2004 · 1.2K citations

Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis.

David Cella, Susan Yount, Mark Sorensen et al. · PubMed · 2005 · 505 citations

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Daniel E. Furst, Michael Schiff, Roy Fleischmann et al. · PubMed · 2003 · 494 citations